A 12-month, Interventional, Open-label, Phase 4 Study in Europe (SHINE) to Investigate the Course of Synovial Hypertrophy as Detected by Joint Ultrasound and MRI in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis.
Latest Information Update: 28 Apr 2025
At a glance
- Drugs Efanesoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Acronyms SHINE
Most Recent Events
- 23 Apr 2025 According to Sobi media release, data from this study presented at WFH 2025 Comprehensive Care Summit in Dubai.
- 08 Jan 2025 Status changed from not yet recruiting to recruiting.
- 08 Jan 2025 New trial record